Investigating what causes cells to become out of control in anaplastic large cell lymphoma
Investigation of epigenetic mechanisms of tumour growth control in anaplastic large cell lymphoma
Understanding the genetics of poor outcome neuroblastoma to improve treatment
A genome wide study of unresectable, MYCN non-amplied, unfavourable histology neuroblastomas in patients older than 18 months of age
Investigating the makeup of malignant rhabdoid tumours
RNA‐sequencing to characterise malignant rhabdoid tumour heterogeneity: a pilot study in archival frozen material
Using the immune system to improve treatment for Hodgkin lymphoma
Targeting GPNMB in Hodgkin lymphoma
Understanding the molecular makeup of low grade glioma and DIPG
Molecular pathophysiology of histone G34R mutated childhood brain tumours: towards the development of novel targeted therapies
Using genetics to find targets for new drugs to treat relapsed neuroblastoma
Characterisation and validation of recurrently mutated genes in relapsed neuroblastoma as targets for novel therapies
Understanding genetic changes in neuroblastoma cells to pave the way for targeted treatments
Investigation of the effects of DNA repair inhibitors in pre-clinical models of neuroblastomas with ATM, MYCN and TP53 abnormalities
Understanding the order of genetic changes that lead to Wilms tumour to improve treatment
Ordering of driver mutations in bilateral Wilms’ tumour
Understanding the biology of malignant rhabdoid tumours to develop targeted treatments
Improved therapeutic targeting in malignant rhabdoid tumours using discovery proteomics analysis